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Inflammatory Markers as Predictors in Primary Liver Cancers with Emphasis on
Chronic Viral Hepatitis
Cortlandt M. Sellers and Hyun S. Kim. Section of Interventional Radiology, Department
of Radiology and Biomedical Imaging, Yale University, Yale School of Medicine, New
Haven, CT, USA.
Inflammation and the immune system significantly impact the development, progression,
and treatment response of primary liver cancers (PLC), namely hepatocellular carcinoma
(HCC) and intrahepatic cholangiocarcinoma (ICC). This retrospective study investigated
the peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio
(PLR), and systemic immune-inflammatory index (SII) as prognostic biomarkers in
patients with PLC in the setting of advanced liver disease and chronic viral hepatitis.
Patients diagnosed with HCC or ICC from 2005 to 2016 were selected from the cancer
registry of a single tertiary care institution. Baseline NLR was calculated within 30 days
prior to treatment and was dichotomized at the median. Kaplan-Meier overall survival
(OS) curves and Cox hazard proportional models were performed. Tumor and liver
reserve parameters were included and analyzed in multivariable analyses (MVA). 581
HCC patients and 109 ICC patients met inclusion criteria. In both forms of PLC, the lowNLR group demonstrated higher median overall survival vs. the high-NLR group
(p<0.01). Log-transformed NLR was also associated with decreased OS, after
multivariable adjustment for confounders (p<0.05). In HCC, viral hepatitis was identified
as a NLR effect modifier (interaction term p<0.05) on MVA. In ICC, advanced liver
disease acted as an effect modifier for the NLR (p<0.05). Lower baseline neutrophil-tolymphocyte ratio is associated with increased overall survival in HCC and ICC and has
more utility than the PLR or the SII as a prognostic marker. The impact of the NLR is
decreased by chronic viral hepatitis in HCC and advanced liver disease in ICC.
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Introduction
Primary liver cancer (PLC) is the seventh most common cancer worldwide (1), the third
most common cause of cancer death (2), and carries a poor prognosis (1, 3, 4).
Hepatocellular carcinoma (HCC) comprises 70-85% of primary liver cancer cases, while
intrahepatic cholangiocarcinoma (ICC) makes up approximately 5-10% (5). In the
United States (U.S.), HCC incidence (6 per 100,000 in 2010) (6) is increasing, and it is
one of the fastest-growing solid tumor malignancies (7, 8). In East Asia the incidence of
HCC is nearly six times that number (35.5 per 100,000), possibly due to high endemic
rates of hepatitis B viral infection (HBV) (9). It is speculated that up to 50% of
hepatocellular carcinoma cases worldwide are HBV-related (10, 11); however, in the
U.S., over a third of HCC cases are associated with hepatitis C virus (HCV) (12). Other
common risk factors for HCC include chronic alcohol consumption, non-alcoholic
steatohepatitis (NASH), and exposure to aflatoxin (13). In recent years in the United
States, the incidence of NASH-related hepatocellular carcinoma has increased (14, 15,
16).

Currently, transplant and resection are the only potentially curative therapies available for
HCC. Locoregional therapies (LRT) such as transarterial chemoembolization (TACE),
thermal ablation, and yittrium-90 radioembolization (Y-90) may be used to treat
inoperable disease and as a bridging therapy in patients awaiting transplant (see Fig. 1,
Fig. 2). Locoregional therapies induce tumor cell death and necrosis through radiation,
physical destruction, or elimination of vascular supply in combination with chemotherapy
(17). One theory proposes that the dying cells release tumor antigens, which are then
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taken up by antigen-presenting cells and which then induce a tumor-specific immune
response (18). Ablation in particular has been shown to promote dendritic cell
maturation, resulting in increased T-cell stimulatory properties (19, 20). This release of
tumor antigens may increase the effectiveness of LRT beyond eradication of visible
lesions.

Fig. 1. Drug-eluting bead-TACE in HCC. A 94-year-old patient with NASH developed a
solitary HCC as seen on MRI (a) and angiography (b). c) Pot-treatment cone beam CT
confirmed drug-eluting bead deposition within the tumor. d) Three-month post-treatment
follow-up MRI demonstrated complete response. Images taken from Dendy et al (21) and
used with permission of the authors.
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Fig. 2. Two cases of infiltrative HCC with portal vein thrombosis following treatment
with a single high-dose Yittrium90-radioembolization. Case 1 slides (A) with
Hematoxylin-eosin stain demonstrates complete pathologic necrosis (arrowhead) of the
tumor bed with glass beads in the necrotic parenchyma (arrow) and a partially
recanalized segmental portal vein (star). Case 2 slides (B) Hematoxylin-eosin stain
demonstrates atrophic fibrotic parenchyma (arrowhead) with complete pathologic
necrosis of the tumor bed with glass beads (arrow). Figures taken from Dendy (2017)
(22) and used with permission of authors.

Intrahepatic cholangiocarcinoma (ICC) has an annual age-standardized incidence rate in
Western countries of <1.5 cases per 100,000 persons (23). A recent review of ICC cases
in the National Cancer Database (NCDB) by Uhlig et al (24) found an increase in the
annual number new of ICC cases from 2004 to 2015 (see Fig. 3). Among intrahepatic
cholangiocarcinomas, there are multiple distinct gross morphologies, namely massforming ICC, periductal infiltrating ICC and intraductal growth ICC (25). Major risk
factors for ICC include primary sclerosing cholangitis, intrahepatic lithiasis, congenital
anomalies of the biliary tree, liver fluke infection, chronic liver disease and cirrhosis, and
less common risk factors include toxic exposure to chemicals such as thorotrast (26). In
addition, it is thought that exposure to viral hepatitis (27), non-alcoholic fatty liver
disease, and perhaps diabetes (28) also increase risk of ICC development.
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Fig. 3. Annual number of ICC cases contained in the NCDB database demonstrating
increasing proportion of non-surgical management and decreased proportion of notreatment. Figure used with permission from Uhlig et al (24).

Intrahepatic cholangiocarcinoma carries a dismal prognosis, with three- and five-year
survival rates of 30% and 18% (29). As few as 15% of patients may present with
resectable disease (30). For patients who are diagnosed at an earlier stage, surgical
resection is recommended whenever possible (31). Unfortunately, up to 36% of surgical
candidates may be found to have unresectable disease on staging diagnostic laparoscopy
(32). The first line of therapy for patients with inoperable ICC consists of systemic
chemotherapy, with a combination of gemcitabine and cisplatin being the standard of
care (31). Recently, locoregional therapies have been used in ICC for palliation (33, 34)
and as an adjuvant therapy alongside systemic chemotherapy (35) or resection (36), with
additional work examining the feasibility of LRT therapies in unresectable disease (37,
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38, 39). An example of the use of radiofrequency ablation (RFA) in a 62-yr-old male
with ICC is shown in Fig. 4.

a)

b)

c)
Fig. 4. RFA in ICC. A 62-year-old male with a solitary ICC lesion as seen on ultrasound
(a) and MRI (b). c) Post-treatment MRI one month later demonstrates the ablation cavity
(arrow) with no evidence of cancer recurrence.

Chronic inflammation and the immune response are integral to the development of
cancers, including those that arise in the liver (40, 41). It is hypothesized that the risk
factors associated with HCC and ICC create a neoplasia-prone environment through liver
injury and subsequent activation of the immune response, leading to the generation of
free radicals as well as the stimulation of cytokines, chemokines, and other growth
factors (40). Activation of cellular proliferation, with its associated increase in cellular
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DNA synthesis, may cause a higher rate of cellular mutations and accelerate
advancement along the cancer pathway (42).

A growing body of work indicates that inflammation and the immune response play key
roles in the development and progression of hepatocellular carcinoma specifically.
Increased levels of tumor infiltrating CD8+ T-cells have been associated with improved
survival in HCC (43), while increased numbers of regulatory T-cells have been
associated with decreased immune response to the tumor, poorer prognosis, and increased
risk of metastasis (44, 45). Immune biomarkers that have been considered prognostic
markers for HCC include the neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), systemic immune-inflammatory index (SII), programmed-death1 (PD-1) receptor, programmed death-ligand 1 (PD-L1), and C-X-C motif chemokine 12
(CXCL12) (43, 46).

The neutrophil-to-lymphocyte ratio was first defined in a cohort of intensive care
oncologic patients, where the severity of their clinical course was found to correspond
with the degree of neutrophilia and lymphocytopenia (47). The NLR is thought to
describe a “narrow relation between innate and adaptive cellular immune responses in
health and diseases” (48) and may be useful in determining the presence of subclinical
inflammation. Since that first study, the NLR has been evaluated as a prognostic marker
in multiple solid organ cancers, including hepatocellular carcinoma, breast, renal cell
carcinoma, melanoma, lung, and head and neck cancer (49, 50, 51, 52, 53, 54), in
addition to acting as an independent predictor of 90-day mortality following non-elective
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hospitalization in patients with hepatic cirrhosis (55). Alongside HCC (56, 57), the
platelet-to-lymphocyte ratio has been studied in breast (58), gastric (59), and non-small
cell lung cancer (60) and the systemic immune-inflammatory index has been examined in
urothelial carcinoma (61).

Despite increasing interest in the NLR and other immune biomarkers in HCC and ICC
(62, 63, 64, 65), few have examined the relevance of these biomarkers in a Western
population. Further, previous research on NLR has focused on populations with high
rates of hepatitis B infection, while hepatitis C tends to be more prevalent in the U.S. It
is also unclear which, if any, of the three inflammatory markers NLR, PLR, and SII is
most effective as a prognostic marker.

Statement of Purpose: The aim of this work was to investigate the relevance of the
NLR, PLR, and SII as prognostic biomarkers in patients with primary liver cancers, with
an emphasis on patients with chronic viral hepatitis and chronic liver disease, and the a
priori hypothesis that the chronic inflammation associated with liver disease and/or viral
hepatitis would alter the prognostic utility of these inflammatory markers.

Methods
Study Population
This study protocol was in compliance with the ethical guidelines set forth by the 1975
Declaration of Helsinki as well as the Health Insurance Portability and Accountability
Act. Yale University institutional review board approval was obtained prior to
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commencement of the study. We retrospectively analyzed adult patients from the Yale
Cancer Center registry diagnosed with HCC or ICC based on histopathological and/or
radiological assessment according to guidelines from the National Cancer Institute and
American Association for the Study of Liver Diseases between 2005 and 2016 and who
received treatments through the hospital system. A flow-chart depicting study design can
be found in Fig. 5.

Treatment allocation was selected by a multi-disciplinary tumor board. For the purposes
of this study, treatment was stratified into systemic therapy, locoregional therapy (LRT),
resection, and transplantation. Systemic therapy consisted of patients who received
chemotherapy with or without radiation oncology treatment. In hepatocellular carcinoma
patients, locoregional therapy was then substratified into transarterial
chemoembolization, ablation, and combined locoregional therapy (combo LRT). HCC
patients who received both transarterial chemoembolization and ablation within a twomonth period were classified as combo LRT, and patients who received systemic therapy
as well as either transarterial chemoembolization or ablation were classified as
transarterial chemoembolization and ablation, respectively. Patients who received
resection or transplant following locoregional therapy were classified as resection and
transplant, respectively. HCC patients who received solely radiation oncology therapy
were excluded due to small sample size (n=8).

For patients with intrahepatic cholangiocarcinoma, treatment allocation was first
stratified into systemic therapy (chemotherapy and/or radiation), catheter-directed
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therapies (including transarterial chemoembolization or TACE and Yittrium-90
radioembolization), ablation, and resection. Catheter-directed therapies and ablation
were then combined into locoregional therapies (LRT). Patients who received LRT or
resection following or in conjunction with systemic therapy were classified as LRT and
resection, respectively. “Non-surgical treatment” consisted of locoregional therapies and
systemic therapies.

Exclusion criteria included individuals under the age of 18, patients with incomplete
treatment or follow-up data, and patients receiving palliative therapy. Patients with a
proven pathologic diagnosis of combined HCC and cholangiocarcinoma were also
excluded from the study.

Cancer
Registry,
HCC n=984

Study
Inclusion
n=581
a)

Exclusion (n=403):
- Incomplete or missing
bloodwork (n=196)
Palliative/Unknown treatment
(n=160)
Radiation only (n=8)
Mixed
HCC/cholangiocarcinoma
(n=15)
Treated elsewhere (n=24)

14

Cancer
Registry,
ICC n=154
Exclusion (n=23):
- Unknown treatment
(n=7)
- Missing bloodwork
(n=16)

Included in
Analyses
n=131

b)
Fig. 5. Flow-charts demonstrating study design. a) for HCC cohort. b) for ICC cohort.

Data Acquisition
Variables reported in the cancer registry included age at diagnosis, gender, ethnicity,
American Joint Committee on Cancer (AJCC) staging, treatment status, and survival
data. Further data was acquired through electronic medical record review, which
explicitly identified therapy status and the temporal sequence of treatments. Additional
chart review for ascites and hepatic encephalopathy data was performed. Along with this
data, baseline laboratory values were used to calculate Child-Pugh and Model for EndStage Liver Disease (MELD) scores. Baseline tumor burden, liver disease, and
performance status were used to calculate Barcelona Clinic Liver Cancer (BCLC) staging
at the time of diagnosis for HCC patients. Due to numbers, patients without cirrhosis
were treated as having Child-Pugh A disease. The Charlson Comorbidity Index (CCI)
(66) was used to quantify non-liver-related disease burden. Viral hepatitis was defined
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via a combination of International Classification of Diseases 9 th Edition codes as well as
HBsAg and HCV Ab laboratory data and included both treated and untreated patients as
well as those currently in treatment and those who had achieved sustained virologic
response. Patients with missing viral hepatitis data (n=4 in HCC, n=49 in ICC) were
considered as “non-viral” hepatitis.

Baseline inflammatory markers, namely the NLR (NLR=neutrophils/lymphocytes),
platelet-to-lymphocyte ratio (PLR=platelets/lymphocytes), and systemic immuneinflammatory index (SII=neutrophils*lymphocytes/platelets), were calculated using lab
values drawn within 30 days prior to treatment.

Statistical Analysis
Pre-treatment immune biomarkers (NLR, PLR, and SII) were dichotomized at the median
for visualization purposes. For all other survival analyses, biomarkers were logtransformed and evaluated as linear predictors. Categorical variables were compared
using the 2 test and continuous variables using the Wilcoxon rank sum test. KaplanMeier methods and log-rank tests were used to estimate overall survival. When survival
curves crossed, the Wilcoxon test was employed in order to account for early survival
losses. The Cox proportional hazards method was used to identify predictors of overall
survival (OS). Non-normally distributed continuous variables were log-transformed for
survival modelling. Patient, liver, and tumor factors that were significant (p<0.05) on
univariate Cox models were included in multivariable models (MVA) to address
confounding.
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An alpha-level of <0.05 was considered statistically significant, and all P-values reported
are two-sided. Calculations were performed using JMP Pro v.13.0.0 (SAS Institute Inc.,
Cary, NC); R version 3.4.3 (R Core Development Team, Vienna, Austria); and RStudio
version 1.1.414 (RStudio Inc., Boston, MA). Additional figures were created using
GraphPad Prism version 7.0a for Mac (GraphPad Software, La Jolla, CA).

Contribution of Authors
All data collection and organization as well as the vast majority of statistical analysis was
conducted by Cortlandt M. Sellers. Hyun S. Kim contributed to study design. Statistical
optimization of biomarkers was first performed by Johannes Uhlig and then repeated and
expanded with the results presented here by Cortlandt M. Sellers.

Results
HCC Demographics
The hepatocellular carcinoma arm of this study consisted of 581 patients who met
inclusion criteria (see Fig. 5a), including 455 (78.3%) men and 126 (21.7%) women, with
an overall mean age of 62.110.0 years. 385 patients (66.2%) were Caucasian. The
etiologies underlying liver disease and HCC were HCV infection (333 patients, 57.3%),
HBV infection (21 patients, 3.6%), combined HBV/HCV infection (17 patients, 2.9%),
alcohol (65 patients, 11.2%), and nonalcoholic steatohepatitis (50 patients, 8.6%). For
additional patient and tumor characteristics in HCC, refer to Table 1 and Table 2. Four
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hundred and eleven patients (70.7%) had a histopathologically proven diagnosis of HCC;
the other 170 (29.3%) had a radiologic diagnosis only.

The most frequent treatment received was transarterial chemoembolization (n=155,
26.7%), and the majority of patients had Child-Pugh A disease (n=351, 60.4%), while
163 patients (28.1%) had Child-Pugh B disease, and 57 patients (9.8%) had Child-Pugh C
disease. Seventy patients received systemic therapy (12.0%), of whom 63 (90%)
received sorafenib, and 7 (10%) received other systemic agents, including regorafenib,
gemcitabine, cisplatin, adriamycin, doxorubicin, atelizumab, and/or bevacizumab.
Additional baseline demographic and tumor variables are provided in Tables 1 and 2.
Mean follow-up time was 33.4 months (SD=30.7 mo) and 333 patients (57.3%) died
during the study period.

ICC Demographics
One hundred and nine patients with intrahepatic cholangiocarcinoma met inclusion
criteria, with a mean follow-up time of 20.0 months (SD=18.1 mo). Eighty-seven
patients (79.8%) died during the study period (see Fig. 5b for study design). The annual
incidence of ICC diagnosis increased over time, from 2 patients diagnosed in 2005 to 14
patients in 2016, with a maximum of 25 cases in 2014.

Mean age among ICC patients was 63.0 years (SD=10.5 yrs), and the population was
50.4% male (n=55) and 78.9% Caucasian (n=86). 78.9% of patients (n=86) were noncirrhotic or had Child-Pugh Class A disease. The mean MELD score was 8.7 (SD=5.0).
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Eleven patients presented with AJCC Stage I disease (10.1%); 25 had Stage II disease
(22.9%); 11 had Stage III disease (10.1%); and 43 patients had Stage IV disease (39.4%).
At diagnosis, 57 patients (52.3%) had multifocal intrahepatic cholangiocarcinoma, 48
patients (44.0%) had bilobar cholangiocarcinoma, 27 patients had vascular invasion
(24.8%), and 46 patients (42.2%) had metastatic disease. Median tumor size at the time
of diagnosis was 6.4 cm (IQR 4.1-8.5). Refer to Table 3 for further baseline patient and
tumor factors.

Among ICC patients, four received thermal ablation (3.7%), 65 patients received
systemic therapy (59.6%), 12 patients had TACE or Y90 (11.0%), and 28 patients
underwent resection (25.7%). Treatment subgroups were then further divided into three
groups: patients who received resection or locoregional therapies (LRT) with or without
subsequent systemic therapy (Group 1, n=35, 32.1%); patients who received systemic
therapy followed by LRT or resection (Group 2, n=9, 8.3%); and patients who received
systemic therapy alone (Group 3, n=65, 59.6%).

Intrahepatic cholangiocarcinoma patients who received surgery had fewer comorbidities
as measured by the Charlson Comorbidity Index (CCI) than patients who had nonsurgical treatment (surgical median CCI 5.0 vs. non-surgical median CC 7.0, p=0.0003).
In addition, the surgical group had slightly lower median MELD scores (6.0) vs. the nonsurgical group (7.0, p=0.0379). Surgical patients also had smaller median tumor size (4.2
cm) vs. non-surgical (7.0 cm, p=0.0006) and higher rates of solitary tumors and unilobar
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disease, and lower rates of extrahepatic metastases (p>0.05). Patients with advanced
AJCC stage disease were less likely to receive surgical treatment (p=0.0006).

Overall Survival of the cohort
The median overall survival time for the hepatocellular carcinoma cohort was 34.9
months, with 1-, 3-, and 5- year survival rates of 75.2%, 48.7%, and 34.9% respectively.
Transplant patients had the highest survival rates, with median OS not reached and 5-year
OS of 86.2%, followed by resection (median OS 51.1 mo), ablation (36.5 mo), combo
LRT (27.9 mo), transarterial chemoembolization (22.2 mo) and systemic therapy (5.1
mo; overall p<0.0001). Fig. 6 demonstrates the Kaplan-Meier cumulative OS curves of

Percent survival
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Fig. 6. Overall Survival of HCC patients by treatment allocation

Median overall survival for the intrahepatic cholangiocarcinoma cohort was 16.5 months
(IQR: 12.9-19.6), with 1-, 3-, and 5-year survival rates of 63.7%, 22.8%, and 12.7%
respectively. Among patients who had documented clearance of their
cholangiocarcinoma (n=27, 24.8%), the confirmed recurrence rate was 51.9% (n=14) vs.
no recurrence (n=13, 48.1%). There were no significant differences across patient, liver,
and tumor characteristics between patients who had recurrence of their ICC and those
who did not.

When stratified by treatment approach, survival among ICC patients was highest in
resection (median OS 43.8 mo, 95% CI: 29.2-62.5 mo), followed by locoregional
therapies (median OS 33.1 mo, 95% CI: 5.6 mo-not reached), systemic therapy (median
OS 11.0 mo, 95% CI: 8.4-13.4 mo, overall p<0.0001). There was a trend towards
improved survival in patients who received locoregional therapies treatment with/without
systemic therapy vs. patients who received systemic therapies alone (p=0.0627). On
multivariable analysis, locoregional therapy demonstrated a survival benefit vs. systemic
therapy (HR 3.98, 95% CI: 1.485-12.660, p=0.0047 ).

Overall survival was highest in Group 1 (39.3 mo), followed by Group 2 (median OS
33.1 mo), then Group 3 (11.0 mo, p<0.0001) (Fig. 7a). In ICC patients with Child-Pugh
A disease, Group 2 demonstrated the highest survival (Group 1 vs. 2 vs. 3: median OS
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36.4 mo vs. 54.6 mo vs. 13.3 mo, p<0.0001) (Fig. 7b). In patients with Child-Pugh class
B disease, there was a non-significant trend towards improved survival for patients in
Group 1 vs. Group 3 (median OS 24.7 mo vs. 7.1 mo, p=0.2175) (Fig. 7c).
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Fig. 7. Overall survival in ICC by treatment group. a) entire cohort; b) Child-Pugh A
patients; c) Child-Pugh B patients

Prognostic Factors for Overall Survival
As shown in Table 4, univariate significant predictors associated with decreased survival
(p<0.05) included older age, increased comorbidities, non-viral hepatitis, higher ChildPugh score, advanced BCLC stage, advanced AJCC stage, increased tumor size,
multifocal tumors, bilobar tumor burden, vascular invasion, and extrahepatic metastases
as well as increased log-transformed alpha-fetoprotein. On multivariable analysis,
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decreased survival was associated with Child-Pugh B disease, BCLC stage D disease,
AJCC stage IV disease, bilobar tumor burden, non-viral hepatitis and log-transformed
alpha-fetoprotein (AFP) (p<0.05) (See Table 5).

Among patients with intrahepatic cholangiocarcinoma, factors significant on univariate
analysis included Charlson comorbidities index, MELD score, AJCC staging, MELD,
tumor size, tumor location, presence of multifocal disease, extrahepatic metastases, and
treatment allocation (Table 6). Factors that were not significant on univariate Cox
analyses included age, gender, race, Child-Pugh score, viral hepatitis status, and vascular
invasion. Significant factors (p<0.05) on MVA included treatment allocation (Table 7).

Immune Biomarkers in HCC
Overall, the HCC cohort had a median platelet count of 117.5*10^3/L (IQR 77.0196.0), with median absolute neutrophil count (ANC) of 3.2*10^3/L (IQR 2.2-4.4) and
median absolute lymphocyte count of 1.3*10^3/L (IQR (0.83-1.8). On univariate Cox
models, increased neutrophils were associated with decreased survival (HR 1.17, 95% CI:
1.11-1.22, p<0.0001), as were increased platelets (HR 1.003, 95% CI: 1.002-1.004,
p<0.001). Absolute lymphocyte count did not significantly affect patient survival on
univariate analyses. After stratifying neutrophils at the median, higher rates of increased
neutrophil count were seen in patients who were older, male, white, had increased
comorbidities, non-viral hepatitis, lower MELD scores, advanced BCLC staging,
advanced AJCC staging, larger tumor size, had bilobar tumors, and patients who received
chemotherapy or resection (p<0.05).
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The median NLR was 2.45 (neutrophils/lymphocytes), median PLR was 96.28
(platelets/lymphocytes), and median SII was 290.05 (neutrophils*platelets/lymphocytes).
As depicted in Fig. 8, there was good to very strong correlation between the
inflammatory markers (PLR and NLR, Spearman =0.62; SII and NLR, =0.74; SII and
PLR, =0.85).

a)

b)

c)
Fig. 8. Correlation between log-transformed inflammatory biomarkers among HCC
patients. a) NLR and PLR. b) NLR and SII. c) PLR and SII

Decreased NLR, PLR and SII were each associated with increased survival after
dichotomization (median OS for above versus below median: log-transformed NLR 45.6
vs. 23.9 months, p<0.001; log-transformed PLR 44.1 vs. 24.9 months, p<0.001; logtransformed SII 44.1 vs. 24.2 months, p<0.001).These findings proved independent from
confounders on separate multivariable Cox regression models (log-transformed NLR: HR
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1.34, 95% CI: 1.10-1.63, p=0.0033; log-transformed PLR: HR 1.32, 95% CI 1.07-1.64,
p=0.0101; log-transformed SII HR 1.17, 95% CI 1.01-1.37, p=0.0415). However, when
including all three biomarkers in one multivariable analysis, only the neutrophil-tolymphocyte ratio remained significant. Therefore, the remainder of our analyses were
conducted using the NLR as the sole biomarker.

Patients in the low-NLR group were more likely to be African American (16.9%) or
Hispanic (17.2%) than patients in the high-NLR group (8.9% and 15.1%, respectively,
p=0.0048). Decreased NLR was associated with lower comorbidity indices vs. the
increased NLR group (median CCI 6 vs. 7, p<0.0001); higher rates of viral hepatitis
(73.8% vs. 52.9%, p<0.0001); higher percentage of Child-Pugh A disease (71.1% vs.
51.9%, p<0.0001), lower MELD score (low-NLR median 8.5 vs. high NLR median 10,
p<0.0001); less advanced BCLC Staging; lower rates of AJCC Stage III/IV disease
(16.3% vs. 28.4%, p=0.0079); higher rates of unilobar tumors; and lower median tumor
size (2.8 cm vs. 3.2 cm, p=0.0003).

Patients in the low-NLR group had lower rates of ethanol-related (7.6%) or NASHrelated HCC (7.2%) versus patients in the high-NLR group (14.8% and 10.0%
respectively, overall p<0.0001). Patients in the low-NLR group were more likely to
receive ablation (17.9%), combo LRT (15.5%), and resection (19.7%) than patients in the
high-NLR group (13.1%, 10.0%, and 12.4% respectively) and less likely to receive
systemic therapy (6.6% vs. 17.5%), transarterial chemoembolization (25.5% vs. 27.8%)
or transplant (14.8% vs. 19.2%, overall p<0.0001). For the patients with a biopsy-proven
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diagnosis of HCC, there was no significant association between tumor differentiation and
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Fig. 9. Survival curves in HCC by NLR group and viral hepatitis. a) entire cohort. b) nonviral hepatitis. c) Viral hepatitis

Log-transformed NLR was associated with decreased OS after multivariable adjustment
for confounders (HR=1.34, 95% CI: 1.102-1.628, p=0.0033). The impact of the NLR
was then tested across treatment subgroups. As shown in Fig. 9a, the low-NLR group
(<median NLR=2.455) demonstrated higher median OS of 45.6 mo vs. the high-NLR
group (median OS 23.9 mo, p<0.0001). Notably, the effect of the NLR was strongest in
systemic therapy (low vs. high NLR: median OS 12.3 mo vs. 4.1 mo, p=0.0008); TACE
(low vs. high NLR: median OS 31.5 mo vs. 16.4 mo, p=0.0018); and resection (low vs.
high NLR: median OS 62.4 mo vs. 42.8 mo, p=0.0357). While a survival disadvantage
was also seen in the low NLR group for ablation (low vs. high NLR: median OS 37.1 mo
vs. 35.2 mo, p=0.2901), combo LRT (low vs. high NLR: median OS 32.6 mo vs. 19.1
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mo, p=0.0873), and transplant (low vs. high NLR: median OS not reached; 5-year OS
92.3% vs. 81.5%, p=0.1061), these did not reach statistical significance.

Severity of Liver Disease and Neutrophil-to-Lymphocyte Ratio
There was no significant difference in the distribution of neutrophils across Child-Pugh
classes; however, decreased lymphocytes were seen with increased Child-Pugh class.
Patients with Child-Pugh class A disease had the highest median absolute lymphocyte
count (1.4, IQR 1.1-1.94), followed by patients with class B disease (median 1.0, IQR
0.7-1.5), and patients with class C disease (median 0.97, IQR 0.64-1.4, overall
p<0.0001). Median platelet count decreased as the severity of liver disease increased
(Class A median 136.5 [IQR 92.8-214.0], class B 99.0 [IQR 65.0-151.0], class C 73.0
[IQR 51.0-111.0], p<0.0001). Median NLR increased with worsening liver disease
(Child-Pugh A 2.2 [1.6-3.3] , Child-Pugh B 3.2 [1.8-4.5], Child-Pugh C 3.6 [2.3-5.5],
p<0.0001). Median PLR and median SII were similar across Child-Pugh groups.

In patients with mild liver disease (Child-Pugh class A), the low-NLR group again
demonstrated improved survival (median OS 54.0 mo) vs. the high-NLR group (29.3 mo,
p<0.0001). Similar results were seen in the Child-Pugh B group (low-NLR vs. highNLR, median OS 26.4 mo vs. 13.6 mo, p=0.0035). However, the neutrophil-tolymphocyte ratio appeared to be less significant in patients with advanced Child-Pugh
Class C liver disease (low-NLR group vs. high-NLR group, median OS 22.3 mo vs. 66.4
mo, p=0.3338). The interaction term between NLR group and Child Pugh class was not
significant on Cox MVA. Of note, 40.4% of patients with Child-Pugh class C disease
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(n=23) received liver transplantation, as compared to 20.9% of patients with Child-Pugh
class B disease (n=34), and 11.7% of patients with class A disease (n=41) (overall
p<0.01).

Viral hepatitis (chronic inflammation) and Neutrophil-to-Lymphocyte Ratio
Hepatocellular carcinoma patients with viral hepatitis had higher survival from diagnosis
of HCC (median OS 38.9 mo) vs. non-viral hepatitis patients (27.7 mo, p=0.0286).
Patients with viral hepatitis were more likely to be male and African American than
patients with non-viral hepatitis (p<0.05) and had lower comorbidities indices, lower
AJCC staging, higher median AFP, decreased median tumor size, and decreased
frequency of bilobar tumors (p<0.05) (See Table 2).

Hepatocellular carcinoma patients without viral hepatitis had higher rates of systemic
therapy, resection, and TACE and lower rates of ablation, combo LRT, and transplant
(p<0.01). While patients with viral hepatitis had higher rates of BCLC stage 0 or A
disease and lower rates of BCLC stage B disease compared to patients with non-viral
hepatitis, rates of BCLC stage C and D disease were similar between the two groups.
HCC patients with and without viral hepatitis were similarly distributed in terms of
Child-Pugh score, MELD score, presence of multifocal tumors, vascular invasion, and
extrahepatic metastases.

HCC patients without viral hepatitis vs. those with viral hepatitis had higher absolute
neutrophil counts (median 3.7*10^3/L vs. 3*10^3/L, p<0.0001) and higher platelet
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counts (median 149*10^3/L vs. 110*10^3/L, p<0.0001). Absolute lymphocyte counts
were similar between the two groups (median 1.3*10^3/L vs. 1.3*10^3/L, p=0.0502).
The median NLR was higher in non-viral hepatitis patients (median NLR=3.0) vs. viral
hepatitis patients (median NLR=2.2, p<0.0001), as was the median PLR (123.3 vs. 78.2,
p<0.0001) and the median SII (445.9 vs. 237.7, p<0.0001).

On multivariable Cox survival analyses, viral hepatitis was identified as an effect
modifier for NLR: the interaction term between hepatitis status and log-transformed NLR
was significant on MVA (p=0.0274). As depicted in Fig. 9b, in non-viral hepatitis
patients NLR below versus above the median was associated with increased survival
(median OS 56.7 vs. 17.6 mo, p<0.0001). However, in the presence of viral hepatitis, the
prognostic relevance was attenuated (Fig. 9c, low vs. high NLR: median OS 41.8 vs. 35.2
mo, Wilcoxon: p=0.0109). Similar findings were observed for a chronic infection group
including all viral hepatitis and human immunodeficiency virus (HIV) patients.

Inflammatory Markers in Intrahepatic Cholangiocarcinoma
Inflammatory Marker Selection
One-hundred and nine ICC patients had laboratory blood work within the 30-day period.
Median absolute neutrophil count for the cohort was 5.2*10^3/L (IQR 3.5-7.2), with
median absolute lymphocyte count of 1.4*10^3/L (IQR 1.0-1.9), and median platelets
of 227*10^3/L (IQR 162-318.5). Decreased absolute neutrophil count and increased
absolute lymphocyte count were associated with a survival benefit on univariate analyses
(p<0.01); however, this survival benefit was not significant on MVA. Platelet count did
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not affect survival on either UVA or MVA. The median NLR for the cohort was 3.5
(IQR 2.3-6.0) and the median PLR was 153.3 (IQR 111.4-219.3) and a median SII of
865.9 (455.0-1333.0). Correlation between inflammatory markers ranged from good
(PLR and NLR, Spearman =0.69) to very strong (PLR and SII, =081; NLR and SII,
p=0.84) (see Fig. 10).
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Fig. 10. Correlation between log-transformed inflammatory biomarkers among ICC
patients. a) NLR and PLR. b) NLR and SII. c) PLR and SII

Decreased NLR was associated with increased survival (p<0.01) (see Fig. 11a), as was
the SII, while dichotomized PLR was not (p=0.3). On MVA, log-transformed NLR
remained an independent prognostic factor (HR 1.81, p<0.05). Neither PLR nor SII were
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independent prognostic factors on MVA (p>0.05), and thus the NLR was used in all
further subgroup analyses.

Neutrophil-to-Lymphocyte Ratio
ICC patients with an NLR greater than the median had larger median tumor size (7.3 cm
vs. 5.6 cm, p=0.0023) and were younger and had lower rates of viral hepatitis. Patients
across NLR groups were similar in terms of age, gender, race/ethnicity, cirrhosis status,
Child-Pugh score, MELD score, AJCC stage, multifocal disease, vascular invasion,
tumor location, and presence of extrahepatic metastases (p>0.5). Patients in the low NLR
group had improved median OS (NLR<=3.5, 23.2 mo, IQR 16.8-32.5 mo) vs. patients in
the high NLR group (NLR>3.5, median OS 12.4 mo, IQR 6.2-14.2 mo). When stratified
into treatment subgroups, the NLR remained a significant factor in patients treated with
systemic therapy (NLR<=3.96 vs. NLR >3.96; median OS 13.4 mo vs. 9.5 mo, p=0.018).
A trend towards improved survival was also seen in the resection (n=28; NLR<=median
vs. NLR >median; median OS 43.8 mo vs. 39.3 mo, p=0.55) and locoregional therapy
subgroups (n=16; NLR<=median vs. NLR >median; median OS 33.1 mo vs. 10.7 mo,
p=0.07).
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Fig. 11. Overall survival by neutrophil-to-lymphocyte ratio and Child-Pugh status in ICC
patients. a) entire cohort b) Child-Pugh A patients. c) Child-Pugh B patients.

Liver status and neutrophil-to-lymphocyte ratio
Patients were further stratified by Child-Pugh score. Due to low numbers (n=1), the
patient with Child-Pugh C disease was excluded. Those with Child Pugh B disease had
more comorbidities as measured by the CCI (10.0) vs. patients with Child Pugh A disease
(6.0, p<0.0001), as well as higher median MELD scores (9.5 vs. 7.0, p=0.0192), and
higher rates of cirrhosis and multifocal ICC (p<0.05). Both Child Pugh groups were
similar in terms of age, gender, race/ethnicity, viral hepatitis, cirrhosis AJCC staging,
tumor size, vascular invasion, treatment allocation, and inflammatory biomarkers.

In Child-Pugh class A (n=86), low NLR had higher OS vs. high NLR (29.2 mo vs. 12.2
mo, p=0.0007) (see Fig. 11b). In Child-Pugh class B (n=14), NLR did not have a
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significant effect on median OS (low vs. high NLR: 8.3 mo vs. 6.2 mo, p=0.6) (see Fig.
11c). Child-Pugh class was further identified as an effect modifier on MVA for logtransformed NLR (p=0.0029).

When stratifying the ICC cohort by viral hepatitis, the NLR continued to be an effective
marker of survival both in non-viral hepatitis (n=90) (low-NLR vs. high-NLR; median
OS 21.8 vs. 13.0 mo, p=0.0270) and in viral hepatitis (n=19) (low-NLR vs. high-NLR;
median OS 29.2 mo vs. 3.8 mo, p=0.0030). Further, the interaction term between logtransformed NLR and viral hepatitis status was nonsignificant on MVA.

Discussion
According to 2018 data from the International Agency for Research on Cancer, primary
liver cancer is the seventh most common cancer worldwide (1) and the third most
common cause of cancer death (2). Estimations from Surveillance, Epidemiology, and
End Results Program (SEER), a governmental database complied in the United States,
concluded that there were 35,600 newly diagnosed cases of PLCs in the U.S. in 2015,
with an estimated 24,500 deaths (67). An estimated 70-85% of primary liver cancers are
due to hepatocellular carcinoma, and as many as 60% of HCC cases globally arise from
HBV or HCV infection (1, 10, 68). While hepatitis B is the predominant viral hepatitis
strain in Asia, hepatitis C is more common in the United States. Several biomarkers have
been postulated as prognostic and predictive makers for HCC, but evidence on their role
in the presence of viral hepatitis and across different treatment approaches is limited.
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Intrahepatic cholangiocarcinoma is the second most common form of primary liver
cancers (69) and has a very poor prognosis. In our cohort, HCC made up approximately
84% of primary liver cancer cases, and ICC comprised roughly 13% of cases.

During the study period, the annual number of HCC cases increased from 13 in 2005 to
62 in 2016, and the annual number of ICC cases diagnosed at our institution increased
from 2 in 2005 to 14 in 2016. It has been noted globally that the incidence of ICC has
been rising over the past few decades (26). Examinations of SEER data have
demonstrated both increased incidence as well as increased mortality over a twenty-year
period from 1973 to 1997 (70). Another study of the SEER database during a similar
time period found that incidence had increased by 165% (71). While the SEER data
demonstrated that the 1-year survival rate increased significantly (from 15.8% during the
first 5 years of the study to 26.3% during the final five years), the five-year survival rate
did not change (2.6% vs. 3.5%). In our cohort, we did not see significant differences in
survival of our ICC patients over time. Although ICC continues to remain a rare liver
malignancy, this increased number of annual cases is concerning and makes the need for
improved types of treatment even more critical.

Locoregional therapies and Unresectable ICC
On multivariable analyses, locoregional therapies demonstrated a survival advantage
compared to systemic therapy alone in patients with unresectable ICC. Multiple forms of
locoregional treatment have been examined in ICC. It is thought that both TACE (33)
and Y-90 (34) are safe and effective as palliative therapies for unresectable disease, and
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TACE has also been used successfully as adjuvant therapy alongside chemotherapy (35)
and surgical resection (36). Upon comparing resection with TACE, Sheuermann et al
(72) found that there was no survival benefit for resection vs. TACE in patients with
positive lymph nodes or positive resection margins after surgery. A meta-analysis
reviewing various forms of LRT treatments delivered through the hepatic artery
concluded that direct chemotherapeutic infusion through the hepatic artery had improved
survival versus TACE, drug-eluting bead TACE, and Y-90 (37). Radiofrequency
ablation has also been shown to prolong survival in inoperable ICC, particularly in
tumors measuring less than 5 cm (38, 73).

Collectively, this evidence suggests that locoregional therapies may be a good are of
continued discovery for future treatment of ICC, particularly in patients whose
comorbidities prevent them from being surgical candidates or who are unable to tolerate
the significant side effects of systemic chemotherapy.

NLR in HCC
For several solid tumors including HCC, an increased neutrophil-to-lymphocyte has been
described as a biomarker associated with decreased overall survival (49, 50, 51, 52, 53,
54). The NLR has been examined in HCC following transplant (74, 75) resection (76,
77), radiofrequency ablation (78, 79, 80), TACE (81, 82, 83), radioembolization (84), and
sorafenib (85, 86, 87). However, while the utility of the NLR has been reported in HBVrelated HCC, few studies have analyzed the effect of the NLR in an HCC population with
high rates of HCV infection (52, 88). Moreover, the majority of studies have been
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conducted in European or Asian populations and their results might not be generalizable
to the more diverse US population. An exception was Sullivan et. al, who utilized
regression models to analyze the predictive value of the NLR in a Western (US)
population of HCC and did not find the NLR to be a significant predictor of survival (89).
Somewhat similarly, Zheng et al examined the impact of six inflammatory markers
including the NLR and PLR on recurrence-free survival (RFS) and OS in HCC in a
Western cohort and found only the PLR to be independently associated with RFS and OS
(90).

Upon assessing the prognostic impact of NLR, PLR, and SII in HCC, NLR emerged as
the single most relevant biomarker and was independently associated with decreased
overall survival. This effect carried through in our subgroup analyses to patients treated
with systemic therapy, TACE, and resection. Although high-NLR patients in the
combined LRT, ablation, and transplant subgroups showed a trend toward decreased
survival with increasing NLR, results did not reach statistical significance, which could
be attributable to smaller sample sizes.

NLR, liver disease, and chronic viral hepatitis in HCC.
The effects of the neutrophil-to-lymphocyte ratio varied with advanced liver disease and
the presence of viral hepatitis. In patients with Child-Pugh class A or B disease, the
neutrophil-to-lymphocyte ratio stratified above and below the median was a significant
prognostic factor for HCC patients, even within Child Pugh scores. However, a high
NLR did not appear to affect survival in patients with more advanced cirrhosis (Child-
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Pugh class C). Similarly, Wang and colleagues (91) reviewed a cohort of HBV-HCC
patients and observed that high NLR or high PLR was not associated with poorer survival
in patients with cirrhosis (Ishak stage 6) and was only associated with poorer survival in
patients with early-to-moderate stage fibrosis (Ishak stages 0-5). It should be noted that
while in our cohort non-cirrhotics were combined with Child-Pugh A patients due to low
numbers, the Child-Pugh measurement is generally only calculated for patients with
cirrhosis and designates increasing liver dysfunction in the context of cirrhosis itself.

In the case of chronic viral hepatitis, while the viral hepatitis and non-viral hepatitis
cohorts were different in terms of BCLC staging, AJCC staging, comorbidities index,
median AFP, mean tumor size, rates of bilobar tumors, and treatment allocation, the
interaction term between log-transformed NLR and hepatitis status was significant on
MVA adjusting for those factors as well as multiple other patient, liver status, and tumor
variables. The NLR was less impactful in patients with viral hepatitis than patients
without viral hepatitis. This may in part be due to the effects of chronic inflammation.
Our findings further demonstrated that HCC patients with chronic viral hepatitis had
lower neutrophil and platelet counts than patients without hepatitis. Viral hepatitis
patients also had a lower median NLR than patients without hepatitis.

Although decreased NLR in our study was associated with fewer co-morbidities (possibly
due to decreased systemic disease burden and decreased systemic inflammation), higher
rates of viral hepatitis, less advanced liver disease, less advanced cancer staging, and
smaller tumors, log-transformed NLR remained an independent predictor of overall

40
survival on multivariable analysis. This suggests that the mechanism of action of NLR
may not be through severity of liver disease or stage of HCC but through other
mechanisms.

Inflammation and intrahepatic cholangiocarcinoma
Cholangiocarcinomas are thought to arise from increased proliferation of the
cholangiocytes that make up the biliary epithelium (92, 93), and ICC in particular is a
very heterogenous tumor. Besides the three distinct gross forms of ICC, there are also
multiple morphologies on the cellular (94) and molecular (95) levels. Risk factors such
as primary sclerosis cholangitis and intrahepatic lithiasis cause cellular injury, which
activates the inflammatory response, leading to increased cholangiocyte proliferation as
well as the production of free radicals and multiple other cytokines and growth and
angiogenic factors, thus continuing the cycle of injury and proliferation (40, 42) and
creating an ideal cellular environment for carcinogenesis (41, 96). This is a similar
pathway to that which has been described in HCC following exposure to hepatitis b virus
in a transgenic mouse model (97), where prolonged injury leads to inflammation,
regenerative hyperplasia, transcriptional deregulation, and aneuploidy before the eventual
development of neoplasia.

Inflammatory Markers in ICC
We observed strong correlation among the neutrophil-to-lymphocyte ratio, platelet-tolymphocyte ratio, and systemic immune-inflammatory index. Upon further analysis,
however, it became clear that the NLR was the sole marker that remained significant on
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multivariable proportional hazards analyses. Likewise, Ha and colleagues (98) studied
the NLR, PLR, and SII as well as soluble programmed cell death ligand-1 in 158 patients
with advanced biliary tract cancers, including ICC, gallbladder carcinoma, extrahepatic
cholangiocarcinoma, and tumors of the ampulla of Vater. They concluded that only NLR
and soluble PD-L1 were independent prognostic factors. As the study of circulating
inflammatory biomarkers continues, it will be important to determine the relative
predictive vs. prognostic values of the neutrophil-to-lymphocyte ratio and other
commonly studied biomarkers.

Neutrophil-to-lymphocyte ratio in ICC
In this cohort, a neutrophil-to-lymphocyte ratio greater than the median was associated
with decreased survival. This survival difference was also seen on subgroup analyses in
among patients who received systemic therapy, and there was a trend towards improved
survival with decreased NLR in the surgery and LRT treatment groups. While this trend
was non-significant, this may have been due to the small numbers in the surgery and LRT
subgroups.

As a marker of that increased inflammation in patients with intrahepatic
cholangiocarcinoma, an increased neutrophil-to-lymphocyte ratio has been associated
with poor prognosis following surgery (62, 65, 99) and chemotherapy (63, 65). It has
been a component of potential prognostic systems (100) as well as nomograms for the
prediction of resection futility (101). A recent meta-analysis that comprised 26 studies
and 4,461 patients concluded that while increased NLR indicated a poor prognosis in
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primary liver cancers, subgroup analyses suggested that the predictive role of NLR in
cholangiocarcinomas might be limited (102). Of note, only 29 of these 4,461 patients
had confirmed ICC.

Neutrophil-to-lymphocyte ratio and liver status
Child-Pugh status was demonstrated to be an effect modifier of the NLR in our cohort. It
should be noted, however, that the Child-Pugh A and Child-Pugh B groups in our cohort
had similar distribution of inflammatory markers. This suggests that there is more at play
beyond the degree of cirrhosis being correlated with the degree of inflammation.
Perhaps, in cases of significant or advanced chronic inflammation, the immune system
becomes fatigued, and the rates of increased neutrophils may be fewer. In light of the
low numbers of Child-Pugh class B patients present in this cohort, there may be smaller
effects and nuances that are being missed due to low-power.

Immune Mechanisms
The interplay between cancer formation and the immune system is complex. Neutrophils
have been found to have both pro-tumor and anti-tumor properties (103). Chronic
inflammation, such as that which occurs in the setting of chronic hepatitis B and hepatitis
C infection, has been associated with increased susceptibility for the development of
cancers (104). Bolte et. al found decreased intra-hepatic mucosal-associated invariant T
cells in patients with chronic HCV as compared to controls (105). These chronic
infections affect the immune system by creating a constant cycle of inflammation,
necrosis, and regeneration and through activation of CD8+ T and natural killer cells as
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well as the production of reactive oxygen species and resultant DNA damage (104, 106,
107).

Although our study focused solely on circulating markers of inflammation, it is plausible
that the NLR may be associated with changes in the tumor microenvironment. There is
no consensus about how the NLR affects the immunologic composition of HCC. For
example, Sun concluded that high levels of intratumoral regulatory T-cells (T-regs) were
associated with poor survival in HCC, while high levels of peritumoral T-regs were not
(108). On meta-analysis, Zhang and colleagues reported that both increased peripheral
blood T-regs and increased intratumoral T-regs were associated with poorer survival
(109).

Wang et al. reviewed NLR and tumor-infiltrating lymphocytes (TILs) in laryngeal
squamous cell carcinoma. Although they found that both high NLR and low TILs were
significantly correlated with decreased OS and recurrence-free survival (RFS), no
correlation between either NLR and TILs or PLR and TILs was evident (110). Other
studies have found the NLR to be related to higher levels of intratumoral neutrophils in
HCC (111). While there is less published work on the NLR in intrahepatic
cholangiocarcinoma, Lin et al (64) examined 102 patients with ICC and saw that higher
PD-1+CD4+ and PD-1+CD8+ T cells were found in the high NLR group while higher
amounts of IFN+CD4+ and IFN+CD8+ T cells were seen in the low NLR group.
Further, the high NLR group experienced an increased density of tumor-infiltrating CD3+
T cells.
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The strengths of the NLR over PLR and SII as seen in this study and others (98) suggest
that it may be the neutrophil component which so strongly drives the effect of the NLR,
and not the lymphocytic component. By releasing further inflammatory cytokines,
neutrophils may increase the rates of cellular injury and continue to propagate an
intercellular and intra-tumoral environment that is ideal for carcinogenesis. Neutrophils
may also be one of the leading carriers of peripheral vascular endothelial growth factor
(VEGF) in patients with cancer. Kusumanto et al. (112) found that cancer patients
carried an increased percentage of total circulating VEGF in granulocytes, including
neutrophils (69%) vs. healthy volunteers (58%). Further, oncologic patients had a
decreased percentage of circulating VEGF in their platelets as compared to controls.
Given the vast heterogeneity of intrahepatic cholangiocarcinomas and hepatocellular
carcinomas at the cellular level, further work is required to establish the precise
relationship between systemic inflammatory markers and local inflammation in HCC and
its microenvironment. In addition, as platelet count is highly linked to progression of
portal hypertension in cirrhotics, the PLR may be less applicable in HCC than in othernon-cirrhotic cancers studied to date.

NLR and Systemic Therapy
Of the treatments visualized in subgroup analyses, the NLR had the strongest effect in
systemic chemotherapy HCC patients, with survival in the low-NLR group being almost
three times as high as survival in the high-NLR group. The majority of these patients
received sorafenib. In the future, when studying the efficacies of systemic therapies, it
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may be prudent to stratify analyses by viral or non-viral HCC, particularly since subgroup
analyses of the SHARP trial demonstrated significant benefit in HCV patients (113), who
would likely have a lower NLR. In addition, it may be possible to utilize the NLR as a
means of determining which patients would benefit most from systemic chemotherapy
among the non-viral HCC population.

This strong survival difference was also seen in intrahepatic cholangiocarcinoma patients
treated with systemic therapy. In light of the poorer survival experienced by patients
treated with systemic therapy in the high-NLR group, primary liver cancer patients with a
high neutrophil-to-lymphocyte ratio and unresectable disease might benefit more from
alternative therapies, such as locoregional treatment, instead of systemic
chemotherapeutic agents.

Limitations
Our study included a diverse, well-characterized cohort regarding age, gender, race, and
ethnicity as well as diverse treatment modalities. Our sample size is a limiting factor in
subgroup analyses; however, our HCC cohort is among the largest studies in which NLR
has been examined. While this study relied on archived records, we limited the NLR
values to within thirty days of HCC or ICC treatment in order to improve standardization.
This study was conducted among a Western (U.S.) population, and results may differ in
other parts of the world.
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Conclusions: After comparing the neutrophil-to-lymphocyte ratio, platelet-tolymphocyte ratio, and systemic immune-inflammation index, it appears that the
neutrophil-to-lymphocyte ratio has the strongest impact as a prognostic marker in
intrahepatic cholangiocarcinoma and hepatocellular carcinoma. This increased survival
is modulated by liver status and chronic viral hepatitis, suggesting that the interplay
between intracellular inflammation and liver parenchymal dysfunction may further affect
survival. The greatest survival difference between low- and high- neutrophil-tolymphocyte groups was seen in patients treated with systemic chemotherapy. Additional
work is needed to further clarify the predictive value of the NLR and how changes in
systemic inflammation are reflected at the level of the tumor microenvironment.
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Tables
Table 1: Baseline characteristics of included patients by NLR
NLR above
NLR below
Total
median
median
P-value
No. 581
(>2.45)
No. 291
No. 290
alpha fetoprotein (AFP)
0.13
13.0 ng/mL

11.0 ng/mL 15.0 ng/mL

Median (IQR)
(5.0 - 127.0) (4.0 - 164.9) (6.0 – 107.0)
neutrophil2.5

3.8

1.7

lymphocyte-ratio

<0.01
(1.7 - 3.8)

(3.1 - 5.5)

(1.3 - 2.0)

(NLR)
platelet-lymphocyte-ratio (PLR)
95.3

<0.01
132.7

70.6

Median (IQR)
(62.5 - 142.8) (87.1 - 195.0) (49.8- 100.1)
systemic immune-inflammatory index (SII)

Median (IQR)

<0.01

290.1

488.5

190.6

(167.0 -

(288.1 –

(114.7 -

529.3)

863.4)

290.7)

Treatment

< 0.01

Resection

93 (16.0%)

36 (12.4%)

57 (19.7%)

Ablation

90 (15.5%)

38 (13.1%)

52 (17.9%)

Systemic Therapy

70 (12.0%)

51 (17.5%)

19 (6.6%)

Combo LRT

74 (12.7%)

29 (10.0%)

45 (15.5%)

TACE

155 (26.7%) 81 (27.8%)

74 (25.5%)
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Transplant
Male Gender

99 (17.0%)

56 (19.2%)

43 (14.8%)

455 (78.3%) 219 (75.5%) 236 (81.1%)
61.0 (56.0 -

62.0 (57.0 -

60.0 (55.0 -

68.0)

70.0)

68.0)

Age

0.10

0.06

Race

<0.01

Black, Non75 (12.9%)

26 (8.9%)

49 (16.9%)

Hispanic

94 (16.2%)

44 (15.1%)

50 (17.2%)

Other/Unknown

27 (4.7%)

10 (3.4%)

17 (5.9%)

Hispanic

White, Non385 (66.3%) 211 (72.5%) 174 (60.0%)
Hispanic
comorbidities
[Charlson

6.0 (5.0 - 8.0) 7.0 (6.0 - 8.0) 6.0 (5.0 - 7.0)

<0.01

Comorbidity Index]
Viral Hepatitis

< 0.01

Viral hepatitis

371 (63.9%) 156 (53.6%) 215 (74.1%)

None

210 (36.1%) 135 (46.4%) 75 (25.9%)

etiology of HCC
HCV

<0.01
333 (57.3%) 135 (46.4%) 198 (68.3%)

HBV

21 (3.6%)

8 (2.8%)

13 (4.5%)

HBV/HCV

17 (2.9%)

13 (4.5%)

4 (1.4%)

Ethanol

65 (11.2%)

43 (14.8%)

22 (7.6%)

NASH

50 (8.6%)

29 (10.0%)

21 (7.2%)
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Other

95 (16.4%)

63 (21.7%)

32 (11.0%)

Child Pugh score

< 0.01

A

351 (60.4%) 149 (51.2%) 202 (69.7%)

B

163 (28.1%) 100 (34.4%) 63 (21.7%)

C

57 (9.8%)

38 (13.1%)

9.0 (7.0 -

10.0 (7.0 -

19 (6.6%)
8.5 (7.0 -

MELD score

<0.01
13.0)

14.0)

11.0)

BCLC score

< 0.01

0 or A

132 (22.7%) 51 (17.5%)

81 (27.9%)

B

84 (14.5%)

C

268 (46.1%) 143 (49.1%) 125 (43.1%)

D

67 (11.5%)

40 (13.7%) 44 (15.25%)

45 (15.5%)

22 (7.6%)

AJCC stage

<0.01

1

266 (45.8%) 124 (42.6%) 142 (49.0%)

2

162 (27.9%) 73 (25.1%)

89 (30.7%)

3

80 (13.8%)

50 (17.2%)

30 (10.3%)

4

43 (7.4%)

28 (9.6%)

15 (5.2%)

Tumor size
Median (IQR)

<0.01
2.9 (2.0 - 4.8) 3.2 (2.2 - 5.8) 2.8 (2.0 - 4.2)

Multifocal HCC

0.08

Yes

233 (40.1%) 127 (43.6%) 106 (36.6%)

No

347 (59.7%) 163 (56.0%) 184 (63.5%)

HCC location

0.04
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Unilobar

411 (70.7%) 192 (66.0%) 219 (75.5%)

Bilobar

162 (27.9%) 91 (31.3%)

71 (24.5%)

95 (16.4%)

60 (20.6%)

35 (12.1%)

0.02

58 (10.0%)

42 (14.4%)

16 (5.5%)

<0.01

Vascular Invasion
Extrahepatic
Metastases

Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT –
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV –
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of Endstage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging;
AJCC – American Joint Committee on Cancer staging system.
Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT –
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV –
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of Endstage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging;
AJCC – American Joint Committee on Cancer staging system.
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Table 2: Baseline characteristics of included patients by viral hepatitis
status
Viral
Non-Viral
Total
Hepatitis
Hepatitis
P-value
No. 581
No. 371
No. 210
alpha fetoprotein (AFP)
<0.01
13.0 ng/mL

17.3 ng/mL

9.0 ng/mL

Median (IQR)
(5.0 - 127.0) (7.0 – 123.5) (4.0 – 147.5)
neutrophil2.5

2.2

3.0

lymphocyte-ratio

<0.01
(1.7 - 3.8)

(1.5 – 3.3)

(2.1 – 4.8)

(NLR)
platelet-lymphocyte-ratio (PLR)

<0.01
123.3

95.3

78.2
(85.9 –

Median (IQR)
(62.5 - 142.8) (55.6 - 125.4)

167.7)
systemic immune-inflammatory index (SII)

Median (IQR)

<0.01

290.1

237.7

445.9

(167.0 -

(141.5 –

(241.3 –

529.3)

409.8)237

753.4)

Treatment

< 0.05

Resection

93 (16.0%)

54 (14.6%)

39 (18.6%)

Ablation

90 (15.5%)

59 (15.9%)

31 (14.8%)

Systemic Therapy 70 (12.0%)

38 (10.2%)

32 (15.2%)

Combo LRT

74 (12.7%)

54 (14.6%)

29 (9.5%)

TACE

155 (26.7%)

94 (25.3%)

61 (29.1%)

67
Transplant
Male Gender

99 (17.0%)

72 (19.4%)

27 (12.9%)

455 (78.3%) 304 (81.9%) 151 (71.9%)
61.0 (56.0 -

59.0 (55.0 –

68.0 (60.0 –

68.0)

64.0)

75.0)

Age

<0.01

0.06

Race

<0.01

Black, Non75 (12.9%)

65 (17.5%)

10 (4.8%)

Hispanic

94 (16.2%)

60 (16.2%)

34 (16.2%)

Other/Unknown

27 (4.7%)

23 (6.2%)

4 (1.9%)

Hispanic

White, Non385 (66.3%) 223 (60.1%) 162 (77.1%)
Hispanic
comorbidities
[Charlson

6.0 (5.0 - 8.0) 6.0 (5.0 - 7.0) 7.0 (6.0-9.0)

<0.01

Comorbidity Index]
Viral Hepatitis

< 0.01

Viral hepatitis

371 (63.9%) 371 (100%)

None

210 (36.1%)

0 (0.0%)

0 (0.0%)
210 (100.0%)

etiology of HCC
HCV

<0.01
333 (57.3%) 333 (89.8%)

0 (0.0%)

HBV

21 (3.6%)

21 (5.7%)

0 (0.0%)

HBV/HCV

17 (2.9%)

17 (4.6%)

0 (0.0%)

Ethanol

65 (11.2%)

0 (0.0%)

65 (31.0%)

NASH

50 (8.6%)

0 (0.0%)

50 (23.8%)
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Other

95 (16.4%)

0 (0.0%)

95 (45.2%)

Child Pugh score

0.81

A

351 (60.4%) 221 (59.6%) 130 (61.9%)

B

163 (28.1%) 106 (28.6%)

C

57 (27.1%)

57 (9.8%)

38 (10.2%)

19 (9.0%)

9.0 (7.0 -

9.0 (7.0 –

10.0 (7.0 –

MELD score

0.11
13.0)

13.0)

13.0)

BCLC score

0.01

0 or A

132 (22.7%)

95 (25.6%)

37 (17.6%)

B

84 (14.5%)

42 (11.3%)

42 (20.0%)

C

268 (46.1%) 173 (46.6%)

95 (45.2%)

D

67 (11.5%)

24 (11.4%)

43 (11.6%)

AJCC stage

0.04

1

266 (45.8%) 173 (46.6%)

93 (44.3%)

2

162 (27.9%) 114 (30.7%)

48 (22.9%)

3

80 (13.8%)

42 (11.3%)

38 (18.1%)

4

43 (7.4%)

25 (6.7%)

18 (8.6%)

Tumor size

<0.01
3.5 (2.4 –

Median (IQR)

2.9 (2.0 - 4.8) 2.7 (2.0 – 4.4)
6.3)

Multifocal HCC

0.26

Yes

233 (40.1%) 155 (41.8%)

78 (37.1%)

No

347 (59.7%) 215 (58.0%) 132 (62.9%)
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HCC location

0.04

Unilobar

411 (70.7%) 265 (71.4%) 146 (69.5%)

Bilobar

162 (27.9%) 103 (27.8%)

59 (28.1%)

95 (16.4%)

56 (15.1%)

39 (18.6%)

0.31

58 (10.0%)

34 (9.2%)

24 (11.4%)

0.67

Vascular Invasion
Extrahepatic
Metastases

Abbreviations used: NLR – neutrophil-to-lymphocyte ratio; AFP – alpha-fetoprotein; IQR – interquartile
range; PLR – platelet-to-lymphocyte ratio; SII – systemic immune-inflammatory index; LRT –
locoregional therapy; TACE – transarterial chemoembolization; HCC – hepatocellular carcinoma; HCV –
hepatitis C virus; HBV – hepatitis B virus; NASH – non-alcoholic steatohepatitis; MELD – Model of Endstage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; AJCC – American Joint Committee
on Cancer staging system.

70
Table 3: Patient, liver, and tumor factors by neutrophil-to-lymphocyte group in ICC
Entire cohort
NLR>3.5
NLR<=3.5
Factor

Age
Male Gender

(n=109)

(n=53)

(n=56)

65.0 (59.0-

60.5 (55.3-

64.0 (57.0-69.5)

72.0)

67.8)

0.0229

55 (50.5%)

24 (45.3%)

31 (55.4%)

0.2927

Race/Ethnicity

p-value

0.1559

Caucasian, nonHispanic

86 (18.9%)

44 (83.0%)

42 (75.0%)

10 (9.2%)

5 (9.4%)

5 (8.9%)

Hispanic

8 (7.3%)

1 (1.9%)

7 (12.5%)

Other/Unknown

5 (4.6%)

3 (5.7%)

2 (3.6%)

Comorbidities Index

7.0 (5.0-9.0)

7.0 (5.0-10.0)

6.5 (4.3-8.0)

0.1644

Viral Hepatitis

19 (17.4%)

5 (9.4%)

14 (25.0%)

0.0292

Cirrhosis

25 (22.9%)

10 (18.9%)

15 (26.8%)

0.3242

Black, NonHispanic

Charlson

Child-Pugh Class

0.5025

A

86 (78.9%)

43 (81.1%)

43 (76.8%)

B

14 (12.8%)

7 (13.2%)

7 (12.5%)

C

1 (0.9%)

1 (1.9%)

0 (0.0%)

7.0 (6.0-9.0)

7.0 (6.0-10.0)

7.0 (6.0-8.3)

MELD Score
AJCC Stage

0.3681
0.2052
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I

11 (10.1%)

2 (3.8%)

9 (16.1%)

II

25 (22.9%)

11 (20.8%)

14 (25.0%)

III

11 (10.1%)

6 (11.3%)

5 (8.9%)

IV

43 (39.4%)

22 (41.5%)

21 (37.5%)

6.4 (4.1-8.5)

7.3 (4.6-11.0)

5.6 (3.5-7.1)

Tumor Size (cm)
Tumor Location

0.0023
0.1571

Unilobar

61 (56.0%)

26 49.1%)

35 (62.5%)

Bilobar

48 (44.0%)

27 (50.9%)

21 (37.5%)

Vascular Invasion

27 (24.8%)

15 (28.3%)

12 (21.4%)

0.4059

Multifocal Disease

57 (52.3%)

28 (52.8%)

29 (51.8%)

0.9131

Metastatic Disease

46 (42.2%)

23 (43.4%)

23 (41.1%)

0.5045

NLR

3.5 (2.3-6.0)

6.0 (4.5-7.4)

2.3 (1.8-2.9)

<0.0001

153.3 (111.4-

215.0

115.0

219.3)

(166.9-294.1)

(86.5-151.3)

1232.2

456.5

865.9 (455.0-

(944.4-

(328.9-

1333.0)

1976.3)

742.0)

PLR

SII
Treatment

<0.0001

<0.0001
0.2698

Resection

28 (25.7%)

10 (18.9%)

18 (32.1%)

LRT

16 (14.7%)

8 (15.1%)

8 (14.3%)

Systemic Therapy

65 (59.6%)

35 (66.0%)

30 (53.6%)

Data presented as median (IQR) or N (%). Abbreviations: NLR – neutrophil-to-lymphocyte ratio; MELD –
Model for End-stage Liver Disease; AJCC – American Joint Committee on Cancer; PLR – platelet-tolymphocyte ratio; SII – systemic immune-inflammation index.
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Table 4. Prognostic factors in HCC on univariate analysis
Predictor
HR
lower.95.
CI
Age
1.02
1.01

upper.95.
CI
1.03

P-value
<0.01

Female Gender (male as reference)

0.79

0.60

1.02

0.08

Race/ethnicity

1.27

0.92

1.72

0.15

Hispanic

1.05

0.77

1.40

0.74

Other/Unknown

0.64

0.33

1.11

0.12

Comorbidities (continuous)

1.17

1.12

1.23

<0. 01

Hepatitis (vs. none)

0.78

0.63

0.98

0.03

MELD score (continuous)

1.00

0.98

1.01

0.59

B

1.73

1.36

2.18

<0.01

C

1.05

0.70

1.51

0.81

B

2.55

1.72

3.81

<0.01

C

2.38

1.72

3.37

<0.01

D

2.16

1.40

3.32

<0.01

1.18

0.89

1.56

0.24

Caucasian (reference)
African American

Child-Pugh Class
A (reference)

BCLC Stage
0 or A (reference)

AJCC
1
2

73
3

3.44

2.53

4.63

<0.01

4

6.25

4.27

8.95

<0.01

1.08

1.06

1.11

<0.01

1.67

1.35

2.07

<0.01

2.24

1.79

2.81

<0.01

Vascular Invasion

4.31

2.85

6.63

<0.01

Metastatic Disease

4.77

3.48

6.44

<0.01

Transplant

0.22

0.12

0.38

<0.01

Ablation

1.79

1.18

2.73

<0.01

TACE

2.69

1.86

3.89

<0.01

Combo LRT

2.36

1.57

3.55

<0.01

Chemo

13.73

9.06

20.79

<0.01

log(AFP)

1.22

1.18

1.27

<0.01

log(NLR)

1.47

1.25

1.73

<0.01

log(PLR)

1.78

1.48

2.14

<0.01

log(SII)

1.59

1.41

1.81

<0.01

Tumor size (continuous)
Tumor Number
Solitary (reference)
Multiple/Multifocal
Tumor Location
Unilobar (reference)
Bilobar

Treatment
Resection (reference)

Abbreviations used: HCC – hepatocellular carcinoma; HR – hazard ratio; CI – confidence interval; MELD
– Model of End-stage Liver Disease; BCLC – Barcelona Clinic Liver Cancer staging; AJCC – American
Joint Committee on Cancer staging system; TACE – transarterial chemoembolization; LRT – locoregional
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therapy; AFP – alpha-fetoprotein; NLR – neutrophil-to-lymphocyte ratio; PLR- platelet-to-lymphocyte
ratio; SII – systemic immune-inflammatory index
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Table 5. Prognostic factors in HCC on multivariable analysis
Predictor
HR
lower.95.CI upper.95.CI
log(NLR)
1.34
1.10
1.63

Pval
<0.01

log(AFP)

1.08

1.02

1.14

<0.01

Viral Hepatitis

0.67

0.50

0.90

<0.01

B

2.18

1.54

3.07

<0.01

C

0.37

0.15

0.98

<0.05

B

1.57

0.96

2.58

0.08

C

1.37

0.91

2.07

0.13

D

5.67

2.54

12.65

<0.01

2

1.29

0.91

1.82

0.15

3

1.82

1.18

2.82

<0.01

4

2.18

1.24

3.80

<0.01

1.78

1.29

2.46

<0.01

Child-Pugh Class
A (reference)

BCLC Stage
0 or A
(reference)

AJCC Stage
1 (reference)

Tumor location
Unilobar (reference)
Bilobar
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Treatment
Allocation
Resection
(reference)
Transplant

0.14

0.07

0.28

<0.01

Ablation

1.26

0.66

2.42

0.49

Combo LRT

2.11

1.12

3.97

0.02

TACE

1.54

0.88

2.69

0.13

Systemic

4.49

2.31

8.74

<0.01

therapy
Interaction term: Log(NLR)*Viral Hepatitis

0.0274

Abbreviations used: HCC – hepatocellular carcinoma; HR – hazard ratio;
CI – confidence interval; NLR – neutrophil-to-lymphocyte ratio;
AFP – alpha-fetoprotein; AJCC – American Joint Committee on Cancer staging system.
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Table 6: Significant Prognostic Markers on Univariate Analysis in ICC patients
Factor
HR
Lower 95% Upper 95%
P-value
Charlson comorbidity

1.23

1.127

1.340

<0.0001

1.06

1.024

1.099

0.0028

II

2.37

0.976

6.624

0.0569

III

3.29

1.110

10.375

0.0319

IV

6.96

2.932

19.644

<0.0001

1.11

1.036

1.179

0.0031

2.01

1.286

3.127

0.0024

Multifocal Tumor

2.21

1.427

3.447

0.0004

Metastases

2.85

1.804

4.506

<0.0001

LRT

1.87

0.746

4.361

0.1728

Systemic

6.85

3.686

13.656

<0.0001

log(NLR)

1.93

1.366

2.698

0.0002

log(PLR)

1.52

1.024

2.275

0.0374

log(SII)

1.37

1.064

1.774

0.0145

Index
MELD
AJCC stage
I (reference)

Tumor size
Tumor location
Unilobar (reference)
Bilobar

Treatment
Resection (reference)
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Abbreviations: MELD – Model for End-stage Liver Disease; AJCC – American Joint Committee on
Cancer; LRT – locoregional therapies; NLR – neutrophil-to-lymphocyte ratio; PLR – platelet-tolymphocyte ratio; SII – systemic immune-inflammation index.
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Table 7: Significant Prognostic Markers on Multivariate Analysis in ICC patients
Factor
HR
Lower
Upper 95%
P-value
95%
Treatment Allocation
Resection (reference)
LRT

1.24

0.388

3.674

0.7070

Systemic

4.92

1.977

13.036

0.0005

Log(NLR)

1.81

1.137

2.867

0.0125

Interaction term: Log(NLR)*Child-Pugh score

0.0029

Abbreviations: HR – hazard ratio; LRT – locoregional therapies; NLR – neutrophil-to-lymphocyte ratio

